BNTX · CIK 0001776985
BioNTech SE
Annual figures as reported, FY2016–FY2025. Ratios and growth rates derived on-page.
Biological Products, (No Diagnostic Substances)
Company profile
Revenue
€2.9B
▲ +4.3% vs FY2024
Net income
−€1.1B
▼ −70.8% vs FY2024
Free cash flow
€280.9M
▲ +456.5% vs FY2024
Diluted EPS
−€4.70
▼ −69.7% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Gross marginOperating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationCapital returned
Cash paid out as dividends and share repurchases
Dividends paid
Diluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedRevenue CAGR
−45.1%
3y
+42.9%
5y
Free cash flow CAGR
−72.3%
3y
Share count change (split-adjusted)
−2.7%
5y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | FCF margin | ROE | ROA | Current ratio |
|---|---|---|---|---|---|---|---|
| FY2025 | 77.6% | −49.0% | −39.6% | 9.8% | −5.9% | −5.2% | 7.54× |
| FY2024 | 80.3% | −47.8% | −24.2% | −2.9% | −3.4% | −3.0% | 7.45× |
| FY2023 | 84.3% | 18.1% | 24.4% | 134.1% | 4.6% | 4.0% | 9.43× |
| FY2022 | 82.7% | 73.0% | 54.5% | 76.5% | 47.0% | 40.5% | 7.43× |
| FY2021 | 84.7% | 80.5% | 54.2% | 4.0% | 86.5% | 65.0% | 4.33× |
| FY2020 | 87.7% | −17.1% | 3.2% | −16.5% | 1.1% | 0.7% | 2.75× |
| FY2019 | 84.0% | −167.1% | −165.0% | −218.3% | −36.3% | −22.5% | 4.05× |
| FY2018 | 89.3% | −42.2% | −37.8% | −69.6% | −18.1% | −7.4% | 3.56× |
| FY2017 | 84.9% | −99.5% | −139.5% | −124.8% | — | — | — |
| FY2016 | — | — | — | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | €2.9B | €2.2B | −€1.4B | −€1.1B | −€4.70 | €456.0M | €175.1M | €22.0B | €2.8B | €19.2B | €7.7B | — |
| FY2024 | €2.8B | €2.2B | −€1.3B | −€665.3M | −€2.77 | €207.7M | €286.5M | €22.5B | €3.1B | €19.4B | €9.8B | — |
| FY2023 | €3.8B | €3.2B | €690.4M | €930.3M | €3.83 | €5.4B | €249.4M | €23.0B | €2.8B | €20.2B | €11.7B | — |
| FY2022 | €17.3B | €14.3B | €12.6B | €9.4B | €37.77 | €13.6B | €329.2M | €23.3B | €3.2B | €20.1B | €13.9B | — |
| FY2021 | €19.0B | €16.1B | €15.3B | €10.3B | €39.63 | €889.7M | €127.5M | €15.8B | €3.9B | €11.9B | €1.7B | — |
| FY2020 | €482.3M | €423.0M | −€82.4M | €15.2M | €0.06 | −€13.5M | €66.0M | €2.3B | €946.8M | €1.4B | €1.2B | — |
| FY2019 | €108.6M | €91.2M | −€181.5M | −€179.2M | −€0.85 | −€198.5M | €38.6M | €797.6M | €304.2M | €493.5M | €519.1M | — |
| FY2018 | €127.6M | €113.9M | −€53.9M | −€48.3M | — | −€58.9M | €29.9M | €653.0M | €386.0M | €267.0M | €411.5M | — |
| FY2017 | €61.6M | €52.3M | −€61.3M | −€86.0M | — | −€52.6M | €24.3M | — | — | −€48.2M | €172.1M | — |
| FY2016 | — | — | — | — | — | — | — | — | — | €31.9M | €303.7M | — |
Latest filings
the most recent regulatory filings3Insider ownership filing2026-06-26 ↗3Insider ownership filing2026-06-26 ↗6-KForeign issuer report2026-06-08 ↗6-KForeign issuer report2026-06-01 ↗6-KForeign issuer report2026-05-22 ↗SCHEDULE 13G/ASEC filing2026-05-15 ↗6-KForeign issuer report2026-05-15 ↗SCHEDULE 13G/ASEC filing2026-05-14 ↗4Insider ownership filing2026-05-13 ↗4Insider ownership filing2026-05-13 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.